# Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients

> **NCT00844597** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** AVI-4658 for Injection

## Key facts

- **NCT ID:** NCT00844597
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-06
- **Final completion:** 2010-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2015-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00844597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00844597, "Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00844597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*